Market research
NAMS NewAmsterdam Pharma Company N.V. Ordinary Shares
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3B
- P/E ratio
- Not available
- Analyst target
- 51.916
- Dividend yield
- Not available
- Beta
- 0.11
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- NL00150012L7
- Market cap
- 3B
- P/E ratio
- Not available
- Analyst target
- 51.916
- Dividend yield
- Not available
- Beta
- 0.11
About
About NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the NAMS discussion.
No comments yet
Start a focused discussion about NAMS.